This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dega, H.
Right arrow Articles by Grosset, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dega, H.
Right arrow Articles by Grosset, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2367-2372, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Activities of Several Antimicrobials against Mycobacterium ulcerans Infection in Mice

Herve Dega, Jerome Robert, Pascale Bonnafous, Vincent Jarlier, and Jacques Grosset*

Laboratoire de Bacteriologie, Faculté de Medecine Pitie-Salpetriere, Paris, France

Received 28 December 1999/Returned for modification 31 March 2000/Accepted 24 May 2000

Mycobacterium ulcerans inoculated into the footpads of mice at 6 × 103 CFU was shown to have a generation time of 6.5 days when estimated from weekly changes in microscopic counts of acid-fast bacilli (AFB) and 7.5 days when calculated from actual CFU enumerated on Lowenstein-Jensen egg medium incubated at 32°C. Footpads became swollen at week 10 (W10) after infection, and all infected control mice were dead at W15 after infection. Daily (5 days/week) treatment with 100 mg of clarithromycin (CLR)/kg of body weight beginning the day after infection prevented swelling of footpads at W10. When initiation of treatment was delayed until obvious footpad swelling was observed, there was a reduction in both the increase in AFB counts and deterioration of swollen footpads and also a prolonged survival of the mice to W18. Mice infected in the hind footpads with 5 × 105 CFU of M. ulcerans were divided into an untreated control group and six treatment groups that received one of the following therapies for 8 weeks: 100 mg of CLR/kg, 25 mg of minocycline (MIN)/kg, 50 mg of sparfloxacin (SPX)/kg, 10 mg of rifampin (RIF)/kg, 10 mg of rifabutin (RBT)/kg, or 100 mg of amikacin (AMK)/kg. After completion of therapy, treated animals were observed for an additional 17 weeks. All control mice and mice treated with CLR, MIN, or SPX exhibited swollen footpads during the observation period. In contrast, of those animals treated with RIF, RBT, or AMK, none had footpad swelling and all inoculated cultures done after the W17 observation remained negative. These results suggest that RIF, RBT, and AMK may be effective in the treatment of human infection with M. ulcerans.

* Corresponding author. Mailing address: Laboratoire de Bacteriologie, Faculte de Medecine Pitie-Salpetriere, 91 Boulevard de l'Hopital, 75634 Paris cedex 13, France. Phone: (33) 1 40 77 97 46. Fax: (33) 1 45 82 75 77. E-mail: bacteriologie{at}chups.jussieu.fr.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2367-2372, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Chauty, A., Ardant, M.-F., Adeye, A., Euverte, H., Guedenon, A., Johnson, C., Aubry, J., Nuermberger, E., Grosset, J. (2007). Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob. Agents Chemother. 51: 4029-4035 [Abstract] [Full Text]  
  • Lefrancois, S., Robert, J., Chauffour, A., Ji, B., Jarlier, V. (2007). Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrob. Agents Chemother. 51: 645-650 [Abstract] [Full Text]  
  • Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans.. Antimicrob. Agents Chemother. 50: 1921-1926 [Abstract] [Full Text]  
  • Etuaful, S., Carbonnelle, B., Grosset, J., Lucas, S., Horsfield, C., Phillips, R., Evans, M., Ofori-Adjei, D., Klustse, E., Owusu-Boateng, J., Amedofu, G. K., Awuah, P., Ampadu, E., Amofah, G., Asiedu, K., Wansbrough-Jones, M. (2005). Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob. Agents Chemother. 49: 3182-3186 [Abstract] [Full Text]  
  • Marsollier, L., Honore, N., Legras, P., Manceau, A. L., Kouakou, H., Carbonnelle, B., Cole, S. T. (2003). Isolation of Three Mycobacterium ulcerans Strains Resistant to Rifampin after Experimental Chemotherapy of Mice. Antimicrob. Agents Chemother. 47: 1228-1232 [Abstract] [Full Text]  
  • Dhople, A. M., Namba, K. (2002). In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans. J Antimicrob Chemother 50: 727-729 [Abstract] [Full Text]  
  • Bentoucha, A., Robert, J., Dega, H., Lounis, N., Jarlier, V., Grosset, J. (2001). Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice. Antimicrob. Agents Chemother. 45: 3109-3112 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»